In this study, we have analyzed the RCTs of PI3K/AKT/mTOR pathway inhibitors to assess their efficacy in all advanced solid cancers and whether they exhibit more efficient anti-tumour properties when combined with other targeted regimens or in cancers with PI3K mutations. This evidence concerns the gene MTOR and cancer.